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Abstract: The prognosis of patients diagnosed with malignant glioma (MG) remains poor. 
However, recent advances in neuro-oncology allowing a better understanding of this particular 
disease have allowed the development of new therapeutics. Many molecular genetic and signal 
transduction pathway targets have been identiﬁ  ed that are now being investigated. Novel 
locoregional treatments, as well as strategies to improve regional delivery, are being evaluated. 
Studies of combinations of these approaches are also underway. In this review, we will discuss 
the current and future therapies under evaluation for the treatment of malignant gliomas.
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Introduction
Primary central nervous system (CNS) tumors represent only 1.35% of all cancers and 
2.2% of all cancer-related deaths.1 Unfortunately, the prognosis of the most frequent 
primary CNS tumors, malignant glioma (MG), remains poor. Glial neoplasms represent 
about 40% of all primary CNS tumors, over three quarters being malignant.2 MG 
include Word Health Organization (WHO) grade III: anaplastic astrocytoma (AA), 
anaplastic oligodendroglioma (AO), and anaplastic oligoastrocytoma (AOA); and 
WHO grade IV: glioblastoma multiforme (GBM), and gliosarcoma.3,4 Despite the 
current standard treatments for MG including surgical resection, radiation therapy, 
and chemotherapy, the survival of patients with MG remains dismal, with a median 
survival of 2 to 3 years for patients with AA and 9 to 12 months for GBM patients.5 
Favorable prognostic factors including youth, absent or minimal neurological signs, 
complete surgical resection, and good performance status have been identiﬁ  ed, but 
unfortunately, clinical recurrence or progression is nearly universal. For patients 
with disease recurrence/progression, available systemic chemotherapies offer modest 
clinical beneﬁ  t with a 6-month progression-free survival (PFS) of less than 15% for 
GBM and 31% for AA,6 and a median overall survival (OS) of 25 weeks and 47 weeks 
for recurrent GBM and AA, respectively.6 In addition to the fatal prognosis, MG affects 
many patients in their forties and ﬁ  fties, frequently terminating promising lives pre-
maturely and depriving young families of parents and spouses. Clearly, more effective 
therapies are desperately needed for patients afﬂ  icted with these tumors.
Temozolomide
Radiation therapy (RT) has been the standard-of-care for MG until recently, while 
systemic chemotherapy has had a limited role.7 However, in a recent phase III 
study, Stupp et al reported results that made temozolomide (TMZ) (Temodar®, 
Temodal®, Schering-Plough Corporation), a DNA methylator and a second-generation 
imidazotetrazine derivative, a standard adjuvant chemotherapy for GBM at ﬁ  rst diag-
nosis. Patients were randomized into 2 groups. One group received concurrent RT 
and daily TMZ at 75 mg/m2, followed by 6 monthly cycles of TMZ (150–200 mg/m2 Biologics: Targets & Therapy 2009:3 16
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orally daily, days 1 through 5, every 28 days) and the control 
group received RT alone. Patients in the RT alone group were 
allowed to receive TMZ at the time of disease progression. 
A median survival of 14.6 months was observed in patients 
treated with concurrent RT and TMZ followed by 6 monthly 
cycles of TMZ, compared to 12.1 months for patients treated 
with RT alone. Also, the 2-year survival rate improved from 
10.4% for RT alone to 26.5% in the RT-TMZ group.8 They 
observed no grade 3 or 4 hematologic toxicities in the RT 
alone group. In the RT-TMZ group, 12 patients (4%) expe-
rienced grade 3 or 4 neutropenia and 9 patients (3%) had 
grade 3 or 4 thrombocytopenia. During the adjuvant TMZ 
therapy of the RT-TMZ group, 14% of patients had any grade 
3 or 4 hematologic toxicities (4% grade 3 or 4 neutropenia, 
11% grade 3 or 4 thrombocytopenia). During the RT period, 
severe infections occurred in 6 patients (2%) in the RT alone 
group and in nine patients (3%) in the RT-TMZ group, 
during adjuvant TMZ therapy, 12 patients (5%) experi-
enced severe infections. Other common non-hematologic 
toxicities included: moderate to severe fatigue (26% RT 
alone group, 33% RT-TMZ group), thromboembolic events 
(6% RT alone group, 4% RT-TMZ), pneumonia (2% RT 
alone group, 1% RT-TMZ group), and opportunistic infec-
tions (one patient in each group). Finally, 2 patients in the 
RT-TMZ group died of cerebral hemorrhage in the absence 
of a coagulation disorder or thrombocytopenia.
Gene methylation is an important cellular mechanism 
of transcription suppression. O6-methylguanine-DNA-
methyltransferase (MGMT) is a critical DNA repair protein, 
which removes chloroethylation, or methylation damage 
from the O6 position of DNA guanines, protecting the tumor 
cells against alkylating and methylating chemotherapeutic 
agents.9 The presence of MGMT gene methylation predicts 
for lack of MGMT expression and subsequent TMZ sen-
sitivity, whereas the absence of MGMT gene methylation 
(unmethylated MGMT) predicts MGMT expression and 
potential TMZ resistance. Analyses of tumor specimens 
from patients treated on the Stupp trial8 were performed 
to determine the methylation status of MGMT and its 
correlation with survival. Patients with MGMT gene meth-
ylation who received RT and TMZ achieved a median PFS 
of 10.3 months and a 2-year survival rate of 46%, compared 
to 5.9 months median PFS and 22.7% 2-year survival rate 
for the patients having MGMT gene methylation but treated 
with RT alone. In comparison, patients with unmethylated 
MGMT achieved a median PFS of 5.3 months and a 2-year 
survival rate of 14% for the RT-TMZ group and 4.4 months 
and 2%, respectively for the group receiving only RT.10 
It was concluded that patients with newly diagnosed GBM 
and MGMT gene methylation beneﬁ  ted the most from the 
addition of TMZ to RT.10
A possible approach to improve the survival of patients 
with unmethylated MGMT is molecules that can reverse 
the process, such as O6-benzylguanine (O6-BG), an 
O6-alkylguanine-DNA alkyltransferase inhibitor. Phase I 
studies of O6-BG with BCNU and TMZ have been limited by 
hematologic toxicities preventing therapeutic dose escalation 
of the chemotherapy.11,12 
Even though the addition of TMZ to RT provides an 
important step forward in the overall treatment of this disease 
and nitrosoureas remain an option, more effective therapies 
are necessary. Several innovative treatment strategies, includ-
ing targeted therapeutics as well as locally administered 
agents, are being studied.
Targeted therapies
The recent success of small-molecule inhibitors of signal 
transduction pathways in other cancers has propelled 
rapid development of similar therapies in the treatment of 
patients with MG. Cellular processes contributing to normal 
homeostasis, once disrupted, can contribute to malignancy and 
this by the presence of common molecular alterations in the 
signal transduction pathways, a communication network of 
regulatory molecules within the cell. Several growth factors, 
hormones, and cytokines regulate these cellular processes. 
Epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF), vascular endothelial growth factor (VEGF), hepato-
cyte growth factor/scatter factor (HGF/SF), and insulin-like 
growth factor (IGF) are some of the relevant growth factor 
pathways in gliomas. Tyrosine kinases are associated with the 
receptors for these pathways. After ligand binding, the recep-
tors undergo dimerization that permits transphosphorylation, 
in which the kinase domain of one receptor phosphorylates one 
or more intracellular tyrosine residues on the second receptor. 
Phosphotyrosine residues recruit adaptor proteins, activating 
downstream effector molecules that initiate signaling cascades 
to regulate gene transcription in the nucleus. MG are known to 
present overexpression or mutations of receptors and intracel-
lular downstream effectors, leading to activation of signaling 
pathways, resulting in uncontrolled cellular proliferation, 
survival, and invasion. Several approaches are available to 
inhibit signaling pathways, from the inhibition of upstream 
growth factor ligands and their receptors, to the inhibition 
of downstream intracellular effectors. Speciﬁ  c inhibitors of 
these targets have shown promise in preclinical and clinical 
trials; however, signiﬁ  cant work remains to maximize the Biologics: Targets & Therapy 2009:3 17
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utility of these treatments to improve patient outcomes. 
The major challenges in the use of kinase inhibitors facing 
the neuro-oncology community are: (1) identiﬁ  cation of the 
optimal therapeutic target(s), (2) establishment of biomarkers 
of tumor sensitivity or resistance, and (3) optimization of 
signaling inhibitor combinations with either other inhibitors or 
cytotoxic agents for efﬁ  cacy and toxicity, as unusual adverse 
events such as neurotoxicity, hypertension and cardiac events 
can occur from those combinations.
Vascular endothelial growth factor
Vascular proliferation, or neoangiogenesis, is a histopatho-
logical characteristic of MG.13,14 One attractive therapeutic 
target for many neoplasms is VEGF, the principal mediator 
of tumor angiogenesis. MG overexpresses VEGF, the levels 
of which correlate directly with tumor vascularity and grade, 
and inversely with prognosis.15–18 Tumor-associated endo-
thelial cells express VEGFR2, creating a paracrine loop of 
angiogenic activation, indicating that VEGF and its receptors 
are important therapeutic targets.17,19
Bevacizumab (BV) is a humanized murine monoclonal 
antibody, binding VEGF-A20,21 and preventing interaction 
and activation of VEGF receptor tyrosine kinases VEGFR1 
and VEGFR2.22 Given in combination with conventional 
chemotherapy, BV signiﬁ  cantly improves the survival of 
patients with metastatic colorectal and lung cancer23,24 and 
PFS of patients with breast cancer.25 BV with irinotecan has 
been approved by the US Food and Drug Administration 
(FDA) for colorectal cancer, as a ﬁ  rst line treatment for 
non-small cell lung cancer in combination with carboplatin 
and paclitaxel, and has obtained accelerated approval 
for metastatic HER2-negative breast cancer patients in 
combination with paclitaxel. Encouraging radiographic 
responses and PFS have been observed in MG exposed to 
BV (Avastin, Genentech, CA, USA) when used in combina-
tion with irinotecan.26 In the ﬁ  rst phase II trial published, a 
radiographic response rate of 63% was observed (1 complete 
response [CR] and 19 partial responses [PRs]). In addition, 
a 6-month PFS of 32% was obtained in GBM patients. Due 
to the encouraging radiographic response rate observed, the 
initial trial was expanded to include a total of 68 patients with 
recurrent MG. In the total group of 68 patients, 35 patients 
had a pathological diagnosis of GBM while 33 had anaplastic 
glioma. Among all 35 recurrent GBM patients, the 6-month 
PFS was 46% (95% CI, 32%–66%) and the 6-month OS was 
77% (95% CI, 64%–92%). Twenty of the 35 patients (57%; 
95% CI, 39%–74%) had at least a PR. One patient developed 
a CNS hemorrhage and 4 patients developed thromboembolic 
complications (deep venous thrombosis and/or pulmonary 
emboli).27 Similarly, among 33 recurrent anaplastic glioma 
patients, the 6-month PFS was 55% (95% CI, 36%–70%) 
and the 6-month OS was 79% (95% CI, 61%–89%). Twenty 
patients (61%) had at least a PR. Signiﬁ  cant adverse events 
were infrequent and included one patient with symptomatic 
CNS hemorrhage and one patient who developed thrombotic 
thrombocytopenic purpura (TTP). The patient with CNS 
hemorrhage required hospitalization and high-dose dexa-
methasone, but made a full recovery following rehabilitative 
therapy. The patient who developed TTP remains on perito-
neal dialysis without sign of disease progression.28
The preliminary results of a phase II, randomized, multi-
center, non-comparative clinical trial of BV alone or in com-
bination with irinotecan for GBM patients at ﬁ  rst or second 
recurrence have been published.29 Eighty-ﬁ  ve patients were 
randomized to the BV alone group and 82 to the combination 
of BV plus irinotecan group. Patients in the BV alone group 
were allowed to receive the combination of BV and irino-
tecan at the time of disease progression at the discretion of 
the investigator. Median OS were comparable at 9.2 months 
(95% CI, 8.2–10.7 months) for the BV alone group and 
8.7 months (95% CI, 7.8–10.9 months) for the combination 
group. However, the 6-month PFS was higher in the com-
bination group (50.3%; 95% CI, 36.8%–63.9%) than in the 
BV-alone group (42.6%; 95% CI, 29.6%–55.5%). Grade 3 
and higher toxicities were higher in the combination group, 
65.8% vs 46.4% for the BV alone group, but grade 5 adverse 
events were more frequent in the BV-alone group (2.4% vs 
1.3% for the combination group).29
The unprecedented increase in PFS and response rate 
observed in MG patients when treated with the combination 
of BV and irinotecan has stimulated research with BV as 
well as other VEGF-directed or antiangiogenic therapies. 
Ongoing studies with agents more commonly used in MG 
patients are evaluating alternative BV-based regimens for 
recurrent MG patients. Two separate single-group studies 
combining BV with protracted, metronomic dosing sched-
ules of either TMZ or etoposide are underway, as well as a 
study combining bortezomib, the ﬁ  rst proteasome inhibitor, 
and BV. Preliminary results on these studies have not yet 
been published. The Radiation Therapy Oncology Group 
(RTOG) is randomizing recurrent GBM patients to receive 
BV with either protracted TMZ (75 mg/m2/day for 21 days 
each month) or irinotecan every 2 weeks. An additional study 
combining BV plus daily erlotinib is also underway.
Potentiation of RT by the inhibition of VEGFR signaling 
in GBM models has been demonstrated in preliminary Biologics: Targets & Therapy 2009:3 18
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studies.30,31 Several single institutional studies are underway 
to evaluate the addition of BV to RT and TMZ for newly 
diagnosed GBM patients. The results of the interim analysis 
for safety and tolerability of the ﬁ  rst 10 patients treated 
by the UCLA group has been published.32 The safety 
analysis showed that one patient experienced a presumed 
radiation-induced optic neuropathy. The toxicities that 
could be potentially related to the treatment combination 
were relatively high incidences of fatigue (20% grade 3–4 
post RT), myelotoxicity (20% and 30% grade 3–4 during 
RT and post RT, respectively), wound breakdown (10% 
and 10% grade 3–4 during RT and post RT, respectively), 
and deep venous thrombosis (30% grade 3–4 post RT) 
and pulmonary embolism (20% grade 3–4 post RT). They 
concluded that the observed toxicities were acceptable 
for continued enrollment toward the overall target group 
of 70 patients. In addition, a multi-center, randomized 
phase III clinical trial for newly diagnosed GBM patients 
is being planned.
Receptor tyrosine kinases (RTKs) inhibitors are typically 
small molecules that competitively block tyrosine or serine/
threonine kinase domains located intracellularly. Preliminary 
results of VEGF RTK inhibitors under evaluation for MG 
patients have been reported. Nine of 16 patients (56%) treated 
with cediranib (AZD2171, AstraZeneca, UK), a potent, 
oral, pan-VEGFR, PDGFR and c-kit inhibitor, achieved a 
radiographic response while 3 additional patients achieved 
stable disease. In addition, 8 of 11 patients (73%) were able 
to reduce pre-treatment corticosteroid dosing. A median 
PFS of 111 days and median OS of 211 days were observed 
in this small cohort of patients. Collaborative imaging 
studies revealed that decreased contrast enhancement was 
accompanied by significant decreases in tumor vessel 
size, permeability, blood volume and ﬂ  ow, consistent with 
“normalization” of tumor vessels. Of note, reversal of 
tumor vessel normalization was observed following drug 
interruption.33 The authors concluded that similar to other 
antiangiogenic therapies that target only tumor endothelium, 
monotherapy with AZD2171 may not improve overall 
survival, suggesting the need to combine cytotoxic therapies 
with AZD2171. A multi-center, randomized clinical trial is 
planned to evaluate cediranib versus lomustine versus the 
combination of cediranib plus lomustine in patients with 
recurrent GBM.
VEGF-TRAP (Regeneron, Inc., NY, USA), a 110 kDa 
soluble protein containing extracellular VEGF receptor 
sequences (VEGFR1 and VEGFR2) fused to a IgG 
backbone,34 acts as a soluble protein decoy VEGF receptor 
that binds circulating VEGF, thereby preventing it from 
interacting with its receptors on tumor endothelial cells.35,36 
VEGF-TRAP potentates RT in prelicinical GBM xeno-
grafts.37 A phase II trial of VEGF-TRAP monotherapy for 
patients with TMZ-resistant recurrent GBM or anaplastic 
glioma at ﬁ  rst relapse was completed by the North American 
Brain Tumor Consortium (NABTC). Forty-eight patients 
were enrolled (32 GBM and 16 anaplastic glioma). Response 
rates of 50% for the anaplastic glioma cohort and 30% for the 
GBM cohort were observed. Grade 3 adverse events included 
fatigue, hypertension, hand-foot syndrome, lymphopenia, 
thrombosis and proteinuria. One ischemic stroke and one 
systemic hemorrhage (grade 4 toxicities) were reported. They 
also observed that VEGF-TRAP induced a rapid and pro-
longed decrease in free levels of VEGF and PIGF, conﬁ  rming 
the sequestration of target growth factors.38 A multi-center 
clinical trial incorporating VEGF-TRAP with RT and TMZ 
is planned for newly diagnosed GBM patients.
Vatalanib (PTK787/ZK222584; Novartis) is a novel, 
oral, small-molecule ATP-mimetic inhibitor of VEGFRs 
that has shown anti-glioma activity in preclinical studies.39 
A phase I multi-institutional trial of PTK787 as monotherapy 
found that the agent was well tolerated with dose-limiting 
toxicities of deep vein thrombosis, liver enzyme elevation, 
insomnia, cerebral edema, fatigue, and nausea/vomiting.40 
Of 31 evaluable patients, one patient presented a PR 
(response rate of 4%) and 20 patients experienced disease 
stabilization (65%).41 Combination of vatalanib with either 
TMZ or lomustine demonstrated response rate of 8% and 
time-to-progression of 16.1 weeks for the TMZ group and 
12.1 weeks for the lomustine group.42
Epidermal growth factor
Another attractive therapeutic target is the epidermal growth 
factor receptor (EGFR). Approximately half of GBM tumors 
exhibit ampliﬁ  cation of EGFR. In addition, EGFR is over-
expressed in many MG independently of the ampliﬁ  cation 
status.43 EGFRvIII, a mutant EGFR variant, is present in 
approximately 40% of GBM tumors, and its expression 
confers a negative prognosis.44 Geﬁ  nitib (ZD1839, Iressa®; 
AstraZeneca) is a novel, oral, low-molecular weight ATP 
mimetic of the anilinoquinazoline family that reversibly 
inhibits the tyrosine kinase activity of EGFR. A phase II trial 
of geﬁ  nitib in ﬁ  rst relapse GBM showed a median event-free 
survival of 8.1 weeks, a 6-month PFS of 17%, and no radio-
graphic responses.45 Other studies of geﬁ  tinib have failed to 
show survival beneﬁ  ts.46,47 Erlotinib (OSI-774, Tarceva®; OSI 
Pharmaceuticals) is an orally active quinazoline derivative Biologics: Targets & Therapy 2009:3 19
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that inhibits EGFR-speciﬁ  c tyrosine phosphorylation and has 
demonstrated antitumor efﬁ  cacy similar to that of geﬁ  nitib in 
preclinical studies. A phase I trial of erlotinib as monotherapy 
or in combination to TMZ demonstrated a response rate of 
14% and a 6-month PFS of 11%.48 Subsequent phase II trials 
of erlotinib have demonstrated response rates of 6% to 25% 
with minimal effect on the progression rate and survival.49,50 
A beneﬁ  t in stratifying patients for EGFR targeted therapies 
has been suggested by two recent studies, demonstrating that 
co-expression of normal PTEN and mutant EGFRvIII,51 and 
combined low levels of AKT and overexpression of EGFR,52 
predict radiographic responses in MG patients treated with 
erlotinib or geﬁ  tinib.
Platelet derived growth factor
Imatinib mesylate (Gleevec®; Novartis, NJ, USA), a 
kinase inhibitor of PDGFR, c-Kit and bcr-abl, has limited 
anti-glioma activity when administered as monotherapy53 
and in combination with RT.54 Speciﬁ  cally, the response rate 
was less than 6% and the 6-month PFS was less than 16% in 
recurrent MG patients.55 In contrast, Dresemann demonstrated 
encouraging anti-glioma activity when imatinib was combined 
with hydroxyurea.56 Two subsequent phase II studies con-
ﬁ  rmed this observation. A response rate of 9% and a 6-month 
PFS of 27% were observed in recurrent GBM patients57 and 
a response rate of 10% and a 6-month PFS of 24% were 
observed in recurrent AA/AO patients.58 A phase II, open-label, 
multi-centre, single-group study evaluating the efﬁ  cacy of ima-
tinib plus hydroxyurea in patients with progressive GBM that 
are receiving enzyme-inducing anticonvulsant drugs (EIACDs) 
has completed enrollment and analysis is underway.
RAF-MEK-ERK
The RAF-MEK-ERK signal transduction pathway, an 
important mediator of dysregulated glioma cell proliferation 
and angiogenesis, also offers potential therapeutic targets. 
In the cytoplasmic part of cell membrane, small guanine 
triphosphate (GTP)-binding proteins, encoded by the RAS 
superfamily of genes, regulate numerous cellular functions 
including proliferation, differentiation, cytoskeletal organi-
zation, protein trafﬁ  cking, and the secretion of angiogenic 
factors. Mutation or ampliﬁ  cation of upstream growth factor 
receptors in gliomas often result in increased RAS activity.59 
Farnesylation is the rate-limiting step in RAS maturation;60 
therefore, several farnesyltransferase inhibitors (FTI) have 
undergone clinical evaluation as RAS targeted therapy. 
However, FTI activity may not be speciﬁ  c to RAS, as many 
other oncoproteins also undergo farnesylation.
Tipifarnib (Zarnestra® R115777; Johnson and Johnson, NJ, 
USA) and lonafarnib (Sarasar®, SCH66336; Schering-Plough, 
NJ, USA) may inactivate RAS by inhibiting farnesyltransferase. 
In a phase I/II study, tipifarnib demonstrated a 6-month PFS 
of 9% in recurrent AA/AO and of 12% in recurrent GBM.61 
Lonafarnib was evaluated in a phase I trial in combination with 
TMZ for patients with prior TMZ failure. A response rate of 
27% and a 6-month PFS of 33% was observed.62 Additional 
molecules inhibiting components of the RAF-MEK-ERK path-
way are under investigation and include AAL881 (Novartis)63 
and sorafenib (Nexavar; Bayer, CT, USA).
PI3K/AKT/mTOR
PI3K, a serine/threonine kinase activated by several receptor 
tyrosine kinases, active RAS, or integrins, regulates several 
malignant phenotypes including apoptosis, cell growth, 
and proliferation. Poor prognosis of MG patients is associ-
ated with the activation of PI3K pathways.64 A constitutive 
activation of PI3K pathways is seen with PTEN loss, 
a common genetic feature in GBM. Activated PI3K 
phosphorylates several downstream effectors including 
AKT, another serine/threonine kinase regulating apoptosis, 
cell growth, and proliferation. Inhibitors of PI3K and AKT 
have undergone preclinical evaluation with encouraging 
results.65 Perifosine (Keryx Biopharmaceuticals, New York, 
NY), an oral AKT inhibitor, administered as an oral loading 
dose of 600 mg on day one followed by 100 mg nightly there-
after is undergoing clinical evaluation in MG. Preliminary 
results showed a response rate of 15%, but updated data are 
to come.66
mTOR, a serine/threonine kinase downstream from 
AKT, is activated not only by AKT but also by RAS path-
ways. Rapamycin (sirolimus; Wyeth, Madison, NJ) and 
its synthesized analogs, temsirolimus (CCI-779; Wyeth), 
everolimus (RAD001; Novartis), and AP23573 (Ariad 
Pharmaceuticals, Cambridge, MA, USA) have been evalu-
ated in clinical trials of MG. Two recent phase II studies of 
temsirolimus in recurrent GBMs by the NABTC and the 
NCCTG have demonstrated modest efﬁ  cacy.67,68 A radio-
graphic response rate of 5% and 36%, and a 6-month PFS of 
2.5% and 7.8%, were observed in the NABTC and NCCTG 
trials, respectively.67,68 The NCCTG trial demonstrated that a 
predictor of radiographic response was a high level of p70s6K 
phosphorylation in tumor at baseline.68 A stimulation of the 
kinase activity of AKT, the immediate upstream effector 
of mTOR, has been demonstrated following the inhibition 
of mTOR in preclinical studies.69 PI-103, a novel inhibitor of 
both PI3K and mTOR, has shown promising activity in both Biologics: Targets & Therapy 2009:3 20
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in vitro and in vivo models of malignant gliomas, possibly 
by blocking the activated PI3K/AKT induced by the mTOR 
inhibition.70
Protein kinase C
High dose tamoxifen has been shown to inhibit protein 
kinase C (PKC), a serine/threonine kinase that regulates 
cell proliferation, invasion and angiogenesis, and to have 
anti-tumor activity in glioma xenografts.71 However, 
tamoxifen mixed results have been reported in clinical 
trials.72–78 Enzastaurin (LY317615; Eli-Lilly, IN, USA), an 
oral serine/threonine kinase inhibitor targeting PKC and 
AKT pathways, induces tumor cell apoptosis and suppresses 
proliferation and angiogenesis.79 A response rate of 29% 
was reported in a phase II trial of recurrent MG.80 Unfortu-
nately, a multi-centered phase III trial of enzastaurin versus 
lomustine in patients with recurrent GBM was discontinued 
at the interim analysis due to lack of beneﬁ  t over the control 
group.81 Patients were randomized 2:1 to receive 6-week 
cycles of 500 mg of enzastaurin daily (125-mg loading dose 
day 1) or lomustine (100–130 mg/m2 on day 1). Enroll-
ment was terminated at 266 patients after a planned interim 
analysis for futility. Median PFS (HR = 1.28 [0.97, 1.70]), 
OS (HR = 1.2 [0.88, 1.65]) and a 6-month PFS rate were 
not different between groups. Four patients discontinued 
enzastaurin due to drug-related serious adverse events 
(AE) (erysipelas, aortic thrombosis, cerebral hemorrhage, 
and convulsion). Eleven (7%) patients on enzastaurin died 
(4 due to AEs, 1 of which was drug-related). In the lomustine 
group, all four (5%) deaths were disease-related. Grade 
3–4 hematological toxicities were signiﬁ  cantly higher for 
lomustine (p  0.001). No anemia, neutropenia, or leuko-
penia occurred on enzastaurin, and only 1 patient had throm-
bocytopenia vs 21 on lomustine. There were no signiﬁ  cant 
differences in grade 3–4 non-hematological toxicities 
between arms. The authors concluded that enzastaurin had 
a better toxicity proﬁ  le but was not superior to lomustine in 
patients with recurrent GBM.81
Integrins
Integrins are cell adhesion molecules important in glioma 
cell invasion, migration, proliferation, survival, and 
angiogenesis by their interactions with multiple extracel-
lular ligands, including vitronectin, ﬁ  bronectin, laminin, 
ﬁ  broblast-growth factor, MMP-2, thrombospondin, ﬁ  brin, 
and ﬁ  brinogen.82–85 Cilengitide (EMD121974; EMD Phar-
maceuticals, NC, USA), an intravenous inhibitor of αvβ3 
and αvβ5 integrin receptors demonstrated the absence of 
dose-limiting toxicity and a radiographic response rate 
of 10% in a phase I trial for MG.86 A phase II study of 
single-agent cilengitide randomized recurrent GBM patients 
to either an intermediate–low dose (500 mg) or an inter-
mediate–high dose (2000 mg). No reproducible toxicities 
were observed in either group, and outcome trended more 
favorably among patients treated at the higher dose level, 
including a 6-month PFS of 15% vs 9.7% and a 12-month 
OS of 37.5% (95% CI 22.7%–54.2%) vs 22% (95% CI 
10.6–37.6).87 Radiographic response occurred in both groups 
but a higher rate was observed among patients treated at 
2000 mg (12.5%) compared to patients treated with 500 mg 
(4.8%). Also, preliminary results of a multi-center trial of 
cilengitide (500 mg twice weekly) in addition to RT and 
TMZ for patients with newly diagnosed GBM patients 
recently reported a 6-month PFS of 69% (95% CI 55%–83%) 
and a 12-month OS of 67% (95% CI 42%–92%). Also, no 
added toxicity was observed when cilengitide was added to 
RT and TMZ.88 Additional studies with cilengitide are ongo-
ing or planned including a trial evaluating the intratumoral 
pharmacodynamics and pharmacokinetics of cilengitide in 
recurrent GBM patients treated with cilengitide prior to a 
planned debulking procedure by the NABTC, a trial evaluat-
ing cilengitide dosed at 2000 mg twice weekly in combina-
tion with RT and TMZ by the New Approaches to Brain 
Tumor Therapy (NABTT) and a multi-center, randomized 
phase III trial for newly diagnosed GBM patients.
Combination therapies
To date, the presence of multiple parallel and/or compensa-
tory pathways and MG heterogeneity likely contributes to 
the limited activity observed with single agent therapy using 
molecularly targeted agents in MG patients. Multiple strate-
gies are being evaluated to help overcome these factors. One 
such strategy is the use of tyrosine kinase inhibitors with 
multiple targets and a second strategy is to combine them 
with cytotoxic agents.
Tyrosine kinase inhibitors with multiple 
targets
AEE788 (Novartis), a dual inhibitor of EGFR and 
VEGFR-2, has shown preclinical efﬁ  cacy in murine models 
of glioblastoma.89 Vandetanib (ZD6474, Zactima®; Astra-
Zeneca), another dual inhibitor of EGFR/VEGFR-2, also 
demonstrated survival beneﬁ  ts in a murine model of intracra-
nial glioma xenografts.90 Clinical trials of vandetanib in MG 
are ongoing. Sunitinib malate (Sutent®, SU11248; Pﬁ  zer), 
an inhibitor of VEGFR-2, PDGFR, c-KIT and FMS-like Biologics: Targets & Therapy 2009:3 21
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tyrosine kinase (FLT)-3, has activity against a subcutaneous 
malignant glioma xenograft.91 A phase II study of sunitinib 
malate in MG is under development.
Targeted therapies combined 
with cytotoxic agents
Promising activity has been observed with imatinib mesylate 
in combination with hydroxyurea (see above). Also, a phase 
I trial of imatinib mesylate with temozolomide is underway.92 
Geﬁ  tinib93 and erlotinib48 have been evaluated in combination 
with TMZ. In an effort to enhance the sensitivity of glioma 
cells to RT, multiple agents are evaluated in combination 
with RT including geﬁ  tinib and erlotinib with or without 
TMZ,94 imatinib mesylate, tipifarnib,95 mTOR inhibitors,96 
vandetanib and BV.
Locoregional therapies
Locoregional therapies are promising approaches due to their 
ability to circumvent the BBB, to minimize systemic toxicity, 
and to concentrate therapy at the primary tumor site, which 
is well-recognized to be the site of tumor recurrence in most 
MG patients.97,98 Gliadel®, a controlled-release, biodegradable 
polymer releasing carmustine (BCNU), was the ﬁ  rst approved 
locoregional therapy for MG.99 Double-blind, randomized, 
placebo-controlled studies using Gliadel implantation in 
surgically resectable cases provided an 8-week survival 
beneﬁ  t and a 2.3-month survival beneﬁ  t in recurrent GBM 
and newly diagnosed MG, respectively.100,101
Delivery of high dose radiation to the tumor bed via 
stereotactic radiosurgery (SRS) is another locoregional 
strategy. However, among newly diagnosed GBM patients, 
no improvement in survival was seen when SRS was added 
to conventional RT plus BCNU chemotherapy.102 The role 
of brachytherapy with 125I-beads implanted into the resec-
tion cavity is limited by a high rate of radiation necrosis 
requiring surgical debulking.103–105 GliaSite®, a commercially 
available product consisting of an aqueous solution of 
organically bound 125I (Iotrex™ [sodium 3-((125)I)-iodo-4-
hydroxybenzene-sulfonate]; Cytyc Corp, Marlborough, MA) 
that delivers low-dose-rate radiation via a temporarily inﬂ  ated 
balloon catheter following resection, is undergoing evaluation 
for newly diagnosed and recurrent MG. Modest results have 
been observed thus far with a 1 year survival rate of 31.1% 
for patient with recurrent WHO grade III and IV.106 Encourag-
ing survival beneﬁ  ts have been noted in single group studies 
evaluating the administration of radiolabeled antitenascin 
monoclonal antibodies into the resection cavity of newly 
diagnosed and recurrent MG patients, with a low rate of radia-
tion necrosis requiring surgical debulking.107,108 In a phase II 
study evaluating the administration of 100 mCi of 131I-m81C6 
followed by chemotherapy to recurrent MG patients, a median 
OS for patients with GBM and WHO grade III tumors of 64 
and 99 weeks respectively was observed.109 A multi-center 
phase III randomized study of 131I-labeled anti-tenascin 
murine monoclonal antibody (Neuradiab; Bradmer Phar-
maceuticals, Inc, Toronto, ON) in combination with RT and 
TMZ versus RT and TMZ in patients with newly diagnosed 
GBM has just been initiated.
Convection enhanced delivery (CED) involves the gradual 
infusion of a therapeutic molecule over 3 to 5 days via micro-
infusion catheters strategically placed in the peritumoral 
region. The consistent positive infusion pressure gradient 
achieved by CED offers the possibility to overcome the 
increased intratumoral interstitial pressure that limits the 
intracranial delivery of systemically administered therapeu-
tics for MG patients.110 In this manner, CED can potentially 
deliver therapeutic agents homogeneously into clinically 
signiﬁ  cant volumes of distribution.111 Convection enhanced 
delivery of IL-13 conjugated with pseudomonas exotoxin 
(cintredekin besudotox, IL13-PE38QQR; NeoPharm, IL, 
USA) had shown encouraging results in phase I/II study for 
MG.112 Unfortunately, a recently completed phase III trial 
with this agent administered by CED failed to achieve a 
survival beneﬁ  t compared to control patients randomized to 
receive carmustine wafers (Gliadel®).113 The evaluation of 
additional molecules or toxins via CED is underway.
Conclusions and future directions
Given the dismal prognosis associated with traditional 
cytotoxic agents for MG patients, there is an urgent need 
for more effective therapies. Thanks to intensive labora-
tory research conducted over the past several years, many 
molecular genetic and signal transduction pathway targets 
have been identiﬁ  ed that are now being evaluated thera-
peutically. The identiﬁ  cation of tumor phenotypes, MGMT 
gene methylation status, EGFRvIII, PTEN, and so on, 
have already demonstrated their signiﬁ  cance (improved 
prognosis of patients with MGMT gene methylation treated 
with TMZ,10 better radiographic response to erlotinib for 
patients demonstrating co-expression of normal PTEN and 
mutant EGFRvIII51). However, additional information and 
understanding is necessary, as the inhibition of one pathway 
is known to induce the activation of a second pathway. In 
addition, novel locoregional treatments as well as strategies 
to improve regional delivery are being evaluated. Given the 
challenges posed by the heterogeneity within and across Biologics: Targets & Therapy 2009:3 22
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malignant glioma tumors, it is likely that combinations of 
these approaches, as well as better identiﬁ  cation of factors 
predictive of response or failure to speciﬁ  c agents among 
patients, will be required as we move forward to improve 
the outcome of MG patients.
Drug and compounds
Temozolomide (Temodar®,Temodal®; Schering-Plough 
Corporation, NJ, USA); O6-benzylguanine; lomustine; 
BCNU; bevacizumab (Avastin®; Genentech, CA, USA); 
Vatalanib (PTK787/ZK222584; Novartis); Gefinitib 
(ZD1839, Iressa®; AstraZeneca, UK); Erlotinib (OSI-
774, Tarceva®; OSI Pharmaceuticals); imatinib mesylate 
(Gleevec®; Novartis, NJ, USA); hydroxyurea; tipifarnib 
(Zarnestra®, R115777; Johnson and Johnson, NJ, USA); 
lonafarnib (Sarasar®, SCH66336; Schering-Plough, NJ, 
USA); AAL881 (Novartis); sorafenib (Nexavar®; Bayer, 
CT, USA); tamoxifen; enzastaurin (LY317615, Eli-Lilly, 
IN, USA); cilengitide (EMD121974, EMD Pharma-
ceuticals, NC, USA); AEE788 (Novartis); vandetanib 
(ZD6474, Zactima®; AstraZeneca); sunitinib malate 
(Sutent®, SU11248; Pﬁ  zer); Gliadel®; stereotactic radio-
surgery; GliaSite®; radiolabeled antitenascin monoclonal 
antibodies; convection enhanced delivery (CED); cintre-
dekin besudotox (IL13-PE38QQR; NeoPharm, IL, USA); 
cediranib (AZD2171; AstraZeneca, UK); VEGF-TRAP 
(Regeneron, Inc., NY, USA); perifosine (Keryx Biophar-
maceuticals, New York, NY, USA); rapamycin (sirolimus; 
Wyeth, Madison, NJ, USA); temsirolimus (CCI-779; 
Wyeth); everolimus (RAD001; Novartis); AP23573 (Ariad 
Pharmaceuticals, Cambridge, MA, USA); PI-103 (AMG-
706; Amgen).
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